Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary medicinal product is substantial. |
Clinical Added Value
| minor |
ESMYA offers a minor improvement in actual benefit (IAB IV) compared to leuprorelin in terms of tolerability in the pre-operative treatment of moderate to severe symptoms in uterine fibroids in adult women of childbearing potential. |
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
Q02mkhv8TLHndwqd
